Sandy Rios
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sandy Rios has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Gen Li
Chengdu Women and Children Central Hospital, Chengdu, Sichuan, 610041, China
1 shared publicationHui-Yuan Hou
Department of Ophthalmology Jacobs Retina Center at Shiley Eye Institute, University of California San Diego, La Jolla, California, United States
1 shared publication- Kristyn Huffman
Department of Ophthalmology, Jacobs Retina Center at Shiley Eye Institute, University of California, San Diego, CA, USA
1 shared publication - Ling Wang
Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Department of Clinical Pharmacy and Pharmacy Administration, West China School of Pharmacy, Sichuan University, Chengdu 610064, China
1 shared publication - Lingyun Cheng
Department of Ophthalmology Jacobs Retina Center at Shiley Eye Institute, University of California San Diego, La Jolla, California, United States
1 shared publication Michael J. Sailor
Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, California, United States
1 shared publication
Latest Publications
- Open Access
- 1 April 2015
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 56 (4) , 2755-63
A Novel Approach of Daunorubicin Application on Formation of Proliferative Retinopathy Using a Porous Silicon Controlled Delivery System: Pharmacodynamics
Purpose:Proliferative vitreoretinopathy (PVR) is the most common cause of poor visual outcomes in association with retinal detachment surgeries and ocular trauma. Daunorubicin (DNR) has shown the strongest efficacy in proliferation inhibition in vitro. However, clinical studies showed only mild effect due to limitations of narrow therapeutic window and short vitreous half-life. Methods:Three milligrams of DNR-loaded particles were intravitreally injected into 18 pigmented rabbits and vitreous samples were collected up to 84 days for analysis. Thirty-seven rabbits were used for a dose-escalation (1, 3, 6 mg) safety and efficacy study in rabbit PVR model using a pre-treatment design. Results:Loading efficiency of DNR was 108.55±12μg per 1mg of the particles. Eighty four days of follow-up did not reveal any adverse reaction. Pharmacokinetic analysis demonstrated a vitreous half-life of 29 days with a maximum DNR concentration of 178 ng/ml and a minimum concentration of 29 ng/ml at day 84. DNR-loaded pSi particles were dosed 8 to 9 weeks before PVR induction and PVR severity score was dose dependent (Spearman ρ=-0.25, p=0.0005). PVR with tractional retinal detachment counted for 88% in the control group, 63% in the low dose group, 14% in the medium dose group, and 0% in the high dose group (Cochran-Armitage Trend Test, Z=8.99, ρ=-0.67, p<0.0001). Conclusions:DNR-loaded pSi particles can safely reside in the vitreous for at least 3 months. pSi based delivery rendered therapeutic window of DNR expanded by a factor of 862 and driven down the minimum effective concentration by a factor of 175.
- 1 April 2015
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 56 (4) , 2755-63
Open AccessA Novel Approach of Daunorubicin Application on Formation of Proliferative Retinopathy Using a Porous Silicon Controlled Delivery System: Pharmacodynamics
Purpose:Proliferative vitreoretinopathy (PVR) is the most common cause of poor visual outcomes in association with retinal detachment surgeries and ocular trauma. Daunorubicin (DNR) has shown the strongest efficacy in proliferation inhibition in vitro. However, clinical studies showed only mild effect due to limitations of narrow therapeutic window and short vitreous half-life. Methods:Three milligrams of DNR-loaded particles were intravitreally injected into 18 pigmented rabbits and vitreous samples were collected up to 84 days for analysis. Thirty-seven rabbits were used for a dose-escalation (1, 3, 6 mg) safety and efficacy study in rabbit PVR model using a pre-treatment design. Results:Loading efficiency of DNR was 108.55±12μg per 1mg of the particles. Eighty four days of follow-up did not reveal any adverse reaction. Pharmacokinetic analysis demonstrated a vitreous half-life of 29 days with a maximum DNR concentration of 178 ng/ml and a minimum concentration of 29 ng/ml at day 84. DNR-loaded pSi particles were dosed 8 to 9 weeks before PVR induction and PVR severity score was dose dependent (Spearman ρ=-0.25, p=0.0005). PVR with tractional retinal detachment counted for 88% in the control group, 63% in the low dose group, 14% in the medium dose group, and 0% in the high dose group (Cochran-Armitage Trend Test, Z=8.99, ρ=-0.67, p<0.0001). Conclusions:DNR-loaded pSi particles can safely reside in the vitreous for at least 3 months. pSi based delivery rendered therapeutic window of DNR expanded by a factor of 862 and driven down the minimum effective concentration by a factor of 175.